Nous sommes fiers de contribuer aux avancées scientifiques sur l'immunité innée et les cellules NK. Depuis notre fondation en 1999, nos études ont été publiées dans de nombreuses revues scientifiques, ce qui souligne notre expertise en matière de modulation des cellules NK et notre engagement en faveur d'une science de la plus haute qualité.
Publications scientifiques
Targeting NK cells
- Vivier et al, 2024. Natural killer cell therapies Nature
- Fenis et al, 2024. New immune cell engagers for cancer immunotherapy Nature Reviews Immunology
- Chiossone, Vivier et al, 2022. Bringing natural killer cells to the clinic J Exp Med.
- Narni-Mancinelli, Vivier et al, 2022. Advancing natural killer therapies against cancer Cell
- Vivier et al, 2021. Tumor-Infiltrating Natural Killer Cells Cancer discovery
- Demaria et al, 2019. Harnessing innate immunity in cancer therapy Nature
- Vivier et al, 2018. Innate Lymphoid Cells: 10 Years On Cell
- Cornen, Vivier et al, 2018. Chemotherapy and tumor immunity, Perspective Science
- Pietra et al, 2016. Human natural killer cells: news in the therapy of solid tumors and high risk leukemias Cancer Immunol Immunother.
- Morvan et al, 2016. NK cells and cancer: you can teach innate cells new tricks Nat Rev Cancer.
- Guillerey et al, 2016. Targeting natural killer cells in cancer immunotherapy Nat Immunol.
- Koehl et al, 2015. Advances in clinical NK cell studies: Donor selection, manufacturing and quality control Oncoimmunology
- Wang et al, 2015. NK cell-mediated antibodydependent cellular cytotoxicity in cancer immunotherapy Front Immunol.
- Pittari et al, 2015. Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies Front Immunol.
- Vivier et al, 2011. Innate or adaptive immunity? The example of natural killer cells Science
- Vivier et al, 2008. Functions of natural killer cells Nat Immunol.
IPH4102
- Willemze et al, 2019. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas Blood
- Van Der Weyden et al, 2018. IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma Expert Opin Investig Drugs.
- Battistella et al, 2017. KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting Blood
- Hurabielle et al, 2017. Usefulness of KIR3DL2 to Diagnose, Follow-Up, and Manage the Treatment of Patients with Sézary Syndrome Clin Cancer Res.
- Wilcox et al, 2017. Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management Am J Hematol.
- Zinzani et al, 2016. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas Crit Rev Oncol Hematol.
- Whittaker et al, 2016. How I treat mycosis fungoides and Sézary syndrome Blood
- Wilcox et al, 2016. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management Am J Hematol.
- Battistella et al, 2016. KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large cell lymphoma Br J Dermatol
- Sicard et al, 2014. IPH4102, a Humanized KIR3DL2 Antibody with Potent Activity against CutaneousT-cell Lymphoma Cancer Research
- Bouaziz et al, 2010. Absolute CD3+ CD158k+ lymphocyte count is reliable and more sensitive than cytomorphology to evaluate blood tumour burden in Sezary syndrome Br J Dermatol
- Willemze et al, 2010. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol.
- Bagot et al, 2001. CD4(+) cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor Blood
NK Cell Engagers
- Vivier et al, 2024. Natural killer cell therapies Nature
- Fenis et al, 2024. New immune cell engagers for cancer immunotherapy Nature Reviews Immunology
- Gauthier et al, 2023. Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123 Nature Biotechnology
- Demaria et al, 2022. Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant Cell Reports Medicine
- Colomar-Carando et al, 2022. Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia Cancer Immunol Res.
- Demaria et al, 2021. Natural killer cell engagers in cancer immunotherapy: Next generation of immuno-oncology treatments European journal of immunology
- Gauthier et al, 2019. Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity Cell
- Mittal et al, 2018. Overcoming Acquired PD-1/PD-L1 Resistance with CD38 Blockade Cancer Discov.
- Cerwenka et al, 2018. Natural killers join the fight against cancer Science
- Chiossone, Vivier et al, 2018. Natural killer cells and other innate lymphoid cells in cancer Nat Rev Immunol.
- Mamessier et al, 2011. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity The Journal of clinical investigation
Monalizumab
- Cascone et al, 2023. Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase 2 NeoCOAST Platform Trial Cancer discovery
- Herbst et al, 2022. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer Journal of Clinical Oncology
- Thorbald van Hall et al, 2019. Monalizumab: inhibiting the novel immune checkpoint NKG2A Journal for Immunotherapy of Cancer
- André, Vivier et al, 2018. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells Cell
Biology of CD94/NKG2A and HLA-E
- Thorbald van Hall et al, 2018. NKG2A Blockade Potentiates CD8 T Cell Immunity Cell
- Haanen, Cerundolo et al, 2018. NKG2A, a New Kid on the Immune Checkpoint Block Cell
- Platonova et al, 2011. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma Cancer Res.
- Gunturi et al, 2005. The role of TCR stimulation and TGF-beta in controlling the expression of CD94/NKG2A receptors on CD8 T cells European journal of immunology
Hematology, proof of concept
- Ruggeri et al, 2016. Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells Haematologica
- Wieten et al, 2014. Clinical and immunological significance of HLA-E in stem cell transplantation and cancer Tissue Antigen
- Godal et al, 2010. NK cell killing of AML and ALL blasts by killer cell Ig-like receptor-negative NK cells after NKG2A and LIR-1 blockade Journal of the American Society for Blood and Marrow Transplantation
ADCC enhancement
- Levy et al, 2009. Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells Innate immun
- Levy et al, 2008. HLA-E protein is overexpressed in primary human colorectal cancer International journal of oncology
IPH5201
- Demaria, Carvelli, Batista, Thibult, Morel A., André, Morel Y., Vély, Vivier et al, 2020. Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19 Cellular & Molecular Immunology
- Perrot et al, 2019. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies Cell Reports
- Bastid et al, 2015. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity Cancer Immunol Res.
- Bastid et al, 2013. CD39 is a promising therapeutic target in oncology Oncogene
IPH5301
- Gao et al, 2014. The roles of CD73 in cancer Biomed Res Int.